Sunaciclib - Aucentra Therapeutics
Alternative Names: AU-07; Oral CDK9 inhibitor - Aucentra TherapeuticsLatest Information Update: 28 Aug 2024
At a glance
- Originator Aucentra Therapeutics
- Class Amines; Antineoplastics; Imidazoles; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Cyclin-dependent kinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in Australia (PO)
- 01 Aug 2021 Sunaciclib - Aucentra Therapeutics is available for licensing as of 26 Jul 2021. https://www.aucentra.com/partners-investors/
- 26 Jul 2021 Phase-I clinical trials in Acute myeloid leukaemia in Australia (PO) before July 2021 (Aucentra Therapeutics pipeline, April 2021)